AGEN Agenus Inc. - Common Stock
NASDAQ · Biotechnology · عرض على SEC EDGAR ↗ إغلاق أكتوبر 2, 2026 10-K/10-Q أغسطس 7, 2026AGEN لقطة سريعة للسهم السعر، القيمة السوقية، مكرر الربحية (P/E)، ربحية السهم (EPS)، العائد على حقوق الملكية (ROE)، نسبة الدين إلى حقوق الملكية، نطاق 52 أسبوعًا
AGEN مخطط سعر السهم OHLCV يومي مع مؤشرات فنية — تحريك وتكبير وتخصيص عرضك
تتكيف دقة الشريط مع الفترة المحددة - مرر مؤشر الفأرة فوق الرسم البياني لرؤية الافتتاح/الأعلى/الأدنى/الإغلاق للشريط.
| تاريخ الاستحقاق | تقسيم | النوع |
|---|---|---|
| 12 إبريل، 2024 | 1-for-20 | عكسي |
| 26 إبريل، 2023 | 1019-for-1000 | أمامي |
| 3 أكتوبر، 2011 | 1-for-6 | عكسي |
حول Agenus Inc. - Common Stock نظرة عامة على الشركة من ويكيبيديا
Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants designed for use with various vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients.
History
Agenus (formerly Antigenics Inc.) was founded in 1994 by Garo H. Armen and Pramod K. Srivastava. The company has pioneered immunotherapies, including heat shock protein-based cancer vaccines, a program that has developed into its Prophage Series of personalized anti-cancer vaccines. Antigenics became a public company in February 2000 on the NASDAQ exchange with the ticker symbol AGEN. In 2000 Agenus acquired Aquila Biopharmaceuticals and a year later it acquired Aronex Pharmaceuticals. In February 2014 the company acquired a European firm, 4-Antibody, along with their portfolio of checkpoint modulators (CPMs) and a platform (Retrocyte Display® technology) to rapidly and efficiently discover new antibodies.
In October 2013, Agenus CEO Garo Armen issued a press release revealing that after an 18-month follow up on the RTS,S Malaria vaccine using QS21-Stimulon®, it was working well enough to support a regulatory filing in 2014. This was the first proof of the efficacy of Agenus's patented "QS-21 Stimulon" adjuvant
In April 2014, Agenus signed a deal with Merck potentially worth $100 million. Under the terms of that deal, Agenus is using its proprietary Retrocyte Display technology to discover antibodies against a pair of undisclosed checkpoint targets for the treatment of cancer. Agenus has advanced two of its own CPM candidates into early drug development and the company is planning to advance several more antibodies in clinical trials.
Today, Agenus is focused on developing a range of immuno-oncology products, including the Prophage vaccines, multiple checkpoint modulators (also known as checkpoint inhibitors or checkpoint antibodies) and its QS21-Stimulon adjuvant. The company's personalized, heat shock protein-based vaccines are in Phase 2 studies. The QS-21 Stimulon adjuvant platform is partnered with GlaxoSmithKline and Janssen. Several of those collaborations involve Phase 3 trials. Altogether, the company and its partners are sponsoring approximately 20 clinical trials of Agenus products.
In August 2023, Agenus announced a strategic restructuring to prioritize its botensilimab and balstilimab (BOT/BAL) clinical programs. The plan included a 25% reduction in its workforce (approximately 85 positions) and the temporary suspension of most preclinical and clinical programs not related to the BOT/BAL combination. The company stated the reorganization was intended to reduce annual operating expenses by approximately $40 million.
In 2025, Agenus sold their CDMO business to Zydus Lifesciences including their two biologics manufacturing sites in Emeryville and Berkeley. In addition, they would partner with Zydus to commercialize their molecules in India.
Key partners and deals
In April 2014, Agenus announced a collaboration and licensing agreement with Merck. The collaboration involved the discovery and development of therapeutic antibodies to two undisclosed Merck checkpoint targets, both thought to be relevant for cancer treatment, in addition to Agenus using its proprietary Retrocyte Display® platform to discover and optimize antibodies against the targets.
In February 2014, Agenus acquired European biotechnology firm 4-Antibody, along with its Retrocyte Display technology and a portfolio of checkpoint modulator antibody candidates .
In March 2012, GlaxoSmithKline acquired two extra rights in the two firms' agreement to use Agenus' QS-21 Stimulon adjuvant. The rights give GSK the first right in negotiation of purchase of Agenus or their assets, the rights expired in 2017 after five years had lapsed.
In June 2025, Agenus entered into a strategic collaboration with Zydus Lifesciences valued at up to $141 million. Under the agreement, Agenus transferred its biologics manufacturing facilities in Emeryville and Berkeley, California, to a new Zydus subsidiary, Zylidac Bio LLC, for an upfront payment of $75 million. The deal also included a $16 million equity investment by Zydus in Agenus common stock and up to $50 million in potential milestone payments. Additionally, Zydus obtained exclusive rights to develop and commercialize the botensilimab and balstilimab (BOT/BAL) combination therapy in India and Sri Lanka, with Agenus eligible for a 5% royalty on net sales. The transaction was formally closed in January 2026.
Product descriptions
Checkpoint modulators (CPMs) interfere with cancers’ ability to “hijack” natural immune defense systems. To protect the body against disease, but without attacking healthy cells, the immune system uses multiple “checkpoint” systems. Some checkpoints stimulate immune responses while others inhibit them. Cancer cells can evolve means to evade checkpoints, and CPMs can reverse that effect, helping the immune system better fight the cancer.
Agenus has programs targeting the checkpoint modulators GITR, OX40, CTLA-4, LAG-3, TIM-3 and PD-1. The company is expanding that portfolio by using a proprietary process to generate fully human therapeutic antibody drug candidates. The platform is a high-throughput approach incorporating IgG format human antibody libraries expressed in mammalian B-lineage cells.
The Prophage series of patient-specific cancer vaccine candidates can also enhance the immune system's response to tumors. Because each cancer is unique, the vaccine is derived from the patient's own tumor sample. To process these samples, Agenus has established a multi-product "good manufacturing practices" facility, which has already helped process over 1,000 tumor samples from across the globe.
The company's QS-21 Stimulon® adjuvant platform strengthens and broadens immune responses to antigens on cancers or foreign invaders’ surfaces. Agenus has multiple partnerships around this product to study its effects with vaccines for diseases including Alzheimer's, melanoma, and malaria. In October 2013, GlaxoSmithKline and Agenus announced positive data from an 18-month follow-up of GSK's RTS,S malaria vaccine with QS21-Stimulon. GSK stated that the treatment was working well enough to support a regulatory filing. RTS,S is the most advanced vaccine for malaria in development.
Agenus is the sole US-manufacturer of a patented and FDA-approved triterpene glycoside extract known as (QS-21, Matrix M), which is a key component in the manufacturing of the Oxford–AstraZeneca COVID-19 as well as the Novavax COVID-19 vaccines. Supplies are tightly controlled, and the US has invoked the US Defence Production Act to preserve vaccine raw materials for its own companies.
المصدر: ويكيبيديا (الإنجليزية), CC BY-SA 4.0 · عرض على ويكيبيديا ↗
أداء 10 سنوات اتجاهات الإيرادات وصافي الدخل والهوامش وربحية السهم
التقييم نسب مكرر الربحية (P/E)، مكرر المبيعات (P/S)، مكرر القيمة الدفترية (P/B)، EV/EBITDA — هل السهم مرتفع السعر أم رخيص؟
| المقياس | اتجاه 5 سنوات | AGEN | متوسط 5 سنوات | متوسط الأقران | الحكم |
|---|---|---|---|---|---|
| P/E (سنوي حالي) | 2.8متوسط 5 سنوات ≈-144.8 | ≈-144.8 | · | · | |
| السعر/المبيعات (سنوي حالي) | 2.7 | · | 6.9 | مقوّم بأقل من قيمته | |
| السعر / القيمة الدفترية (الربع الأخير) | -1.8 | · | · | · | |
| EV / EBITDA | -16.7 | · | · | · | |
| السعر / التدفق النقدي الحر (سنوي حالي) | -3.6 | · | · | · | |
| السعر / التدفق النقدي (سنوي حالي) | -3.6 | · | · | · | |
| EV / Revenue (القيمة المؤسسية / الإيرادات) | 3.0 | · | · | · | |
| EV / FCF (القيمة المؤسسية / التدفق النقدي الحر) | -4.4 | · | · | · | |
| السعر / القيمة الدفترية الملموسة (الربع الأخير) | -1.8 | · | · | · |
يتم حساب الوسيط النظير على أساس موحد لكل مقياس وقد لا يتطابق دائمًا مع الأساس السنوي الحالي/الربع الأخير المعروض لهذا السهم.
الربحية هامش الربح الإجمالي والتشغيلي والصافي؛ العائد على حقوق الملكية (ROE)، العائد على الأصول (ROA)، العائد على رأس المال المستثمر (ROIC)
| المقياس | اتجاه 5 سنوات | AGEN | متوسط 5 سنوات | متوسط الأقران | الحكم |
|---|---|---|---|---|---|
| هامش التشغيل (سنوي حالي) | 27.3%متوسط 5 سنوات ≈-82.1% | ≈-82.1% | -123.1% | من الدرجة الأولى | |
| EBITDA Margin (هامش EBITDA) | -17.7%متوسط 5 سنوات ≈-82.1% | ≈-82.1% | -123.1% | من الدرجة الأولى | |
| Pretax Margin (هامش ما قبل الضريبة) | -2.7% | · | -72.9% | من الدرجة الأولى | |
| هامش صافي الربح (سنوي حالي) | 69.3%متوسط 5 سنوات ≈-127.4% | ≈-127.4% | -150.6% | من الدرجة الأولى | |
| العائد على الأصول (سنوي حالي) | 51.4%متوسط 5 سنوات ≈-43.8% | ≈-43.8% | -38.5% | من الدرجة الأولى | |
| ROE (سنوي حالي) | -33.2%متوسط 5 سنوات ≈416.3% | ≈416.3% | -38.3% | من الدرجة الأولى | |
| ROIC | 8.9% | · | -20.5% | من الدرجة الأولى |
الصحة المالية الديون، السيولة، الملاءة المالية — قوة الميزانية العمومية
| المقياس | اتجاه 5 سنوات | AGEN | متوسط 5 سنوات | متوسط الأقران | الحكم |
|---|---|---|---|---|---|
| الدين / حقوق الملكية (الربع الأخير) | -0.2متوسط 5 سنوات ≈-0.0 | ≈-0.0 | 0.1 | ديون منخفضة | |
| النسبة الحالية (الربع الأخير) | 0.3متوسط 5 سنوات ≈0.9 | ≈0.9 | 5.4 | سيولة منخفضة | |
| Quick Ratio (النسبة السريعة) | 0.0متوسط 5 سنوات ≈0.7 | ≈0.7 | 5.1 | سيولة منخفضة | |
| Long-Term Debt / Equity (الدين طويل الأجل / حقوق الملكية) | 0.0متوسط 5 سنوات ≈-0.0 | ≈-0.0 | 0.0 | ديون منخفضة |
النمو نمو الإيرادات وربحية السهم وصافي الدخل: مقارنة بالعام السابق (YoY)، متوسط النمو السنوي المركب لـ 3 سنوات (3Y CAGR)، متوسط النمو السنوي المركب لـ 5 سنوات (5Y CAGR)
| المقياس | اتجاه 5 سنوات | AGEN | متوسط 5 سنوات | متوسط الأقران | الحكم |
|---|---|---|---|---|---|
| Revenue YoY (الإيرادات مقارنة بالعام السابق) | 10.4%متوسط 5 سنوات ≈40.9% | ≈40.9% | · | · | |
| Revenue CAGR 3Y (معدل نمو الإيرادات السنوي المركب لـ 3 سنوات) | 5.2%متوسط 5 سنوات ≈-1.1% | ≈-1.1% | · | · | |
| Revenue CAGR 5Y (معدل نمو الإيرادات السنوي المركب لـ 5 سنوات) | 5.3% | · | · | · |
كفاءة رأس المال معدل دوران الأصول، معدل دوران المخزون، معدل دوران المستحقات
| المقياس | اتجاه 5 سنوات | AGEN | متوسط 5 سنوات | متوسط الأقران | الحكم |
|---|---|---|---|---|---|
| Asset Turnover (دوران الأصول) | 0.5متوسط 5 سنوات ≈0.5 | ≈0.5 | 0.4 | من الدرجة الأولى | |
| Receivables Turnover (دوران المستحقات) | 102.1متوسط 5 سنوات ≈77.6 | ≈77.6 | 4.5 | من الدرجة الأولى | |
| Revenue / Employee (الإيرادات / الموظف) | ≈$1.4M | · | · | · |
القيمة · ≈ متوسط 5 سنوات · متوسط الصناعة · حكم مقارنة بالمتوسط
سجل الأرباح ربحية السهم الفعلية مقابل التقديرات، نسبة المفاجأة %، معدل التجاوز، تاريخ الأرباح التالي
| الفترة | تقرير | EPS Actual | EPS المتوقع | المفاجأة |
|---|---|---|---|---|
| 30 يونيو، 2026 | أغسطس 10, 2026 | $-0.01 | $0.05 | -119.6% |
| 31 مارس، 2026 | مايو 11, 2026 | $0.00 | $2.14 | -100.0% |
| 31 ديسمبر، 2025 | $-0.31 | $-1.07 | 71.1% | |
| 30 سبتمبر، 2025 | $1.94 | $2.02 | -3.9% | |
| 30 يونيو، 2025 | $-1.00 | $1.38 | -172.4% | |
| 31 مارس، 2025 | $-1.03 | $-1.69 | 39.0% | |
| 31 ديسمبر، 2024 | $-2.04 | $-2.59 | 21.3% |
الأساسيات الكاملة جميع المقاييس حسب السنة — قائمة الدخل، الميزانية العمومية، التدفق النقدي
قائمة الدخل
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $114M | $103M | $156M | $98M | $296M | $88M | $150M | $37M | $43M | $23M | $25M | $7M | |
| Cost of Revenue | $1M | $486.0K | $3M | $11M | $3M | $2M | · | · | · | · | · | $0 | |
| R&D Expense | $79M | $156M | $235M | $187M | $179M | $143M | $168M | $125M | $116M | $95M | $70M | $22M | |
| SG&A Expense | $54M | $72M | $79M | $81M | $76M | $59M | $46M | $37M | $34M | $33M | $28M | $21M | |
| Operating Income | $-20M | $-120M | $-160M | $-179M | $26M | $-117M | $-70M | $-124M | $-104M | $-107M | $-81M | $-43M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | · | · | $1M | |
| Interest Income | $345.0K | $3M | $6M | $2M | · | · | · | · | · | · | · | · | |
| Other Non-op | $72M | $6M | $37.0K | $11M | $5M | $-2M | $28.0K | $-2M | $2M | $-2M | $-6M | $2M | |
| Pretax Income | $-3M | $-232M | $-257M | · | · | · | · | · | $-121M | $-127M | $-93M | $-42M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $-5M | $0 | |
| Net Income | $-3M | $-232M | $-257M | $-231M | $-29M | $-183M | $-112M | · | $-121M | $-127M | $-88M | $-42M | |
| EPS (Basic) | $0.00 | $-10.59 | $-13.75 | $-15.64 | $-0.11 | $-1.05 | · | · | · | · | · | · | |
| EPS (Diluted) | $0.00 | $-10.59 | $-13.75 | $-15.64 | $-0.11 | $-1.05 | · | · | · | · | · | · | |
| Shares (Basic) | 29,734,000 | 21,473,000 | 17,894,000 | 14,087,000 | 228,919 | 172,504 | · | · | · | · | · | · | |
| Shares (Diluted) | 29,734,000 | 21,473,000 | 17,894,000 | 14,087,000 | 228,919 | 172,504 | · | · | · | · | · | · | |
| EBITDA | $-20M | $-120M | $-160M | $-179M | $26M | $-117M | $-70M | $-124M | $-104M | $-107M | $-81M | · |
الميزانية العمومية
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3M | $40M | $76M | $179M | $292M | $100M | $62M | $53M | $60M | $71M | $137M | $26M | |
| Short-term Investments | · | · | · | $15M | $15M | · | · | · | · | $5M | $35M | $15M | |
| Receivables | $2M | $407.0K | $26M | $3M | $2M | $1M | $16M | $938.0K | $1M | $11M | $10M | $463.0K | |
| Inventory | · | · | · | · | · | · | $0 | $55.0K | $79.5K | $88.2K | $88.2K | $95.7K | |
| Prepaid Expense | $785.0K | $2M | $8M | $14M | $20M | $11M | $7M | $19M | $11M | $3M | $2M | $1M | |
| Other Current Assets | $1M | $2M | $2M | $3M | $3M | $2M | $1M | $1M | $1M | $838.5K | $582.3K | $640.0K | |
| Current Assets | $133M | $46M | $112M | $213M | $332M | $114M | $87M | $75M | $74M | $91M | $184M | $43M | |
| PP&E (Net) | $15M | $120M | $133M | $133M | $60M | $27M | $26M | $25M | $26M | $26M | $15M | $6M | |
| PP&E (Gross) | $63M | $193M | $195M | $187M | $111M | $74M | $69M | $63M | $60M | $57M | $45M | $34M | |
| Accum. Depreciation | $47M | $73M | $62M | $54M | $51M | $47M | $43M | $38M | $34M | $31M | $29M | $28M | |
| Goodwill | $24M | $24M | $25M | $25M | $25M | $25M | $23M | $23M | $23M | $22M | $23M | $18M | |
| Intangibles | $3M | $3M | $4M | $6M | $8M | $11M | $11M | $12M | $14M | $16M | $19M | $7M | |
| Other Non-current Assets | $3M | $6M | $9M | $4M | $10M | $4M | $1M | $1M | $1M | $1M | $1M | $1M | |
| Total Assets | $227M | $226M | $314M | $414M | $466M | $215M | $155M | $136M | $138M | $157M | $242M | $75M | |
| Accounts Payable | $83M | $61M | $61M | $41M | $30M | $17M | $14M | $14M | $8M | $5M | $4M | $2M | |
| Accrued Liabilities | $34M | $35M | $45M | $38M | $42M | $29M | $31M | $25M | $22M | $28M | $14M | $6M | |
| Current Liabilities | $323M | $221M | $256M | $189M | $157M | $130M | $122M | $68M | $56M | $41M | $29M | $9M | |
| Capital Leases | $10M | $55M | $63M | $63M | $42M | $34M | $8M | · | · | · | · | · | |
| Other Non-current Liabilities | $259.0K | $738.0K | $5M | $15M | $2M | $2M | $4M | $3M | $3M | $5M | $8M | $3M | |
| Long-term Debt | $45M | $33M | $13M | $13M | $14M | $20M | $14M | $13M | $163M | $131M | $114M | $6M | |
| Total Debt | $45M | $33M | $13M | $13M | $14M | $20M | $14M | $13M | $163M | $131M | $114M | · | |
| Common Stock | $353.0K | $236.0K | $197.0K | $3M | $3M | $2M | $1M | $1M | $1M | $877.9K | $863.9K | $627.2K | |
| Paid-in Capital | $1.91B | $1.86B | $1.80B | $1.64B | $1.52B | $1.26B | $1.06B | $1.01B | $952M | $867M | $851M | $716M | |
| Retained Earnings | $-2.18B | $-2.18B | $-1.96B | $-1.71B | $-1.49B | $-1.47B | $-1.28B | $-1.18B | $-1.03B | $-905M | $-779M | $-691M | |
| Treasury Stock | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| AOCI | $-439.0K | $-1M | $-955.0K | $915.0K | $1M | $3M | $-1M | $-2M | $-2M | $-2M | $-2M | $-2M | |
| Stockholders' Equity | $-271M | $-326M | $-160M | $-61M | $34M | $-204M | $-225M | $-172M | $-76M | $-39M | $71M | $23M | |
| Liabilities + Equity | $227M | $226M | $314M | $414M | $466M | $215M | $155M | $136M | $138M | $157M | $242M | $75M | |
| Shares Outstanding | 35,320,397 | 23,634,670 | 19,718,662 | · | · | · | · | · | · | · | · | · |
التدفق النقدي
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $10M | $13M | $14M | $7M | $7M | $7M | $7M | $6M | $6M | $5M | $2M | $2M | |
| Stock-based Comp | $14M | $17M | $23M | $18M | $20M | $10M | $10M | $8M | $12M | $13M | $7M | $5M | |
| Deferred Tax | $0 | $0 | $0 | · | · | · | · | · | · | · | $-5M | · | |
| Amort. of Intangibles | $300.0K | $500.0K | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $462.0K | |
| Operating Cash Flow | $-77M | $-158M | $-224M | $-175M | $10M | $-139M | $-19M | $-131M | $-94M | $-80M | $-47M | $-38M | |
| CapEx | $6.0K | $576.0K | $10M | $53M | $34M | $3M | $5M | $4M | $3M | $13M | $4M | $3M | |
| Investing Cash Flow | $1M | $27.0K | $3M | $-34M | $-43M | $-4M | $-5M | $-4M | $2M | $18M | · | $-17M | |
| Debt Issued | · | · | · | · | · | $6M | · | · | $15M | · | $109M | · | |
| Net Debt Issued | $-2M | · | · | · | · | $6M | · | · | $15M | · | $109M | · | |
| Financing Cash Flow | $37M | $123M | $120M | $96M | $225M | $184M | $31M | $128M | $81M | $-2M | · | $53M | |
| Net Change in Cash | $-39M | $-36M | $-102M | $-113M | $192M | $41M | $9M | $-7M | $-11M | $-65M | $111M | $-2M | |
| Free Cash Flow | $-77M | $-159M | $-234M | $-228M | $-24M | $-143M | $-23M | $-135M | $-97M | $-92M | $-51M | · |
الربحية
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -17.7% | -116.4% | -102.1% | -183.0% | 8.7% | -133.0% | -46.7% | -336.6% | -242.1% | -476.1% | -325.2% | · | |
| Net Margin | -2.7% | -224.5% | -164.7% | -235.3% | -9.7% | · | · | · | -281.5% | -562.6% | -354.1% | · | |
| Pretax Margin | -2.7% | · | · | · | · | · | · | · | -281.5% | -562.6% | -375.8% | · | |
| EBITDA Margin | -17.7% | -116.4% | -102.1% | -183.0% | 8.7% | -133.0% | -46.7% | -336.6% | -242.1% | -476.1% | -325.2% | · | |
| ROA | -1.4% | -86.0% | -70.8% | -52.4% | -8.4% | · | · | · | -81.7% | -63.6% | -55.5% | · | |
| ROE | 1.0% | 95.5% | 232.3% | 1718.9% | 34.0% | · | · | · | 210.0% | -803.7% | -187.5% | · | |
| ROIC | 8.9% | · | · | · | · | · | · | · | -119.0% | -117.4% | -41.1% | · |
السيولة والملاءة
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.4 | 0.2 | 0.4 | 1.1 | 2.1 | 0.9 | 0.7 | 1.1 | 1.3 | 2.2 | 6.4 | · | |
| Quick Ratio | 0.0 | 0.2 | 0.4 | 1.0 | 2.0 | 0.8 | 0.6 | 0.8 | 1.1 | 2.1 | 6.3 | · | |
| Debt / Equity | -0.2 | -0.1 | -0.1 | -0.2 | 0.4 | -0.1 | -0.1 | -0.1 | -2.2 | -3.3 | 1.6 | · | |
| LT Debt / Equity | 0.0 | -0.1 | -0.1 | -0.2 | 0.4 | -0.1 | -0.1 | -0.1 | -1.9 | -3.3 | 1.6 | · |
الكفاءة
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.4 | 0.4 | 0.2 | 0.9 | 0.5 | 1.0 | 0.3 | 0.3 | 0.1 | 0.2 | · | |
| Receivables Turnover | 102.1 | 7.9 | 10.9 | 46.0 | 221.1 | 10.1 | 17.4 | 35.5 | 6.9 | 2.1 | 4.8 | · |
لكل سهم
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-7.68 | · | · | · | · | · | · | · | · | · | · | · | |
| Revenue / Share | $3.84 | $4.82 | $436.77 | $347.92 | · | · | · | · | · | · | · | · | |
| Cash Flow / Share | $-2.60 | $-7.37 | $-626.46 | $-622.46 | · | · | · | · | · | · | · | · | |
| Cash / Share | $0.08 | · | · | · | · | · | · | · | · | · | · | · | |
| EPS (TTM) | $0.00 | $-10.59 | $-13.75 | $-15.64 | $-0.11 | $-1.05 | $-0.81 | · | $-1.13 | $-1.13 | $-1.13 | $-1.13 |
معدلات النمو
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 10.4% | -33.8% | 59.5% | -66.8% | 235.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 5.2% | -29.5% | 21.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 5.3% | · | · | · | · | · | · | · | · | · | · | · |
التقييم (آخر 12 شهرًا)
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $114M | $103M | $156M | $98M | $296M | $88M | $150M | $37M | $43M | $23M | $25M | $7M | |
| Net Income TTM | $-3M | $-232M | $-257M | $-231M | $-29M | $-183M | $-112M | $-162M | $-121M | $-127M | $-88M | $-42M | |
| Market Cap | $111M | · | · | · | · | · | · | · | · | · | · | · | |
| Enterprise Value | $153M | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | · | -0.3 | -1.2 | -3.0 | -574.5 | -59.4 | -98.6 | · | -56.6 | -71.6 | -78.9 | -69.0 | |
| P/S | 1.0 | · | · | · | · | · | · | · | · | · | · | · | |
| P/B | -0.4 | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | -1.4 | · | · | · | · | · | · | · | · | · | · | · | |
| P / FCF | -1.4 | · | · | · | · | · | · | · | · | · | · | · | |
| EV / EBITDA | -7.6 | · | · | · | · | · | · | · | · | · | · | · | |
| EV / FCF | -2.0 | · | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 1.3 | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | 0.00% | -386.5% | -82.8% | -33.2% | -0.17% | -1.7% | -1.0% | · | -1.8% | -1.4% | -1.3% | -1.5% |
قائمة الدخل
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35M | $34M | $34M | $30M | $26M | $24M | $27M | $25M | $24M | $28M | $84M | $24M | $25M | $23M | $28M | $23M | |
| Cost of Revenue | $0 | $0 | $0 | $642.0K | $243.0K | $137.0K | $118.0K | $146.0K | $115.0K | $107.0K | $260.0K | $303.0K | $254.0K | $2M | $8M | $308.0K | |
| R&D Expense | $15M | $12M | $8M | $24M | $27M | $22M | $34M | $41M | $37M | $44M | $67M | $51M | $59M | $57M | $53M | $46M | |
| SG&A Expense | $8M | $7M | $12M | $11M | $16M | $16M | $21M | $17M | $17M | $17M | $21M | $19M | $20M | $18M | $25M | $18M | |
| Operating Expenses | $23M | $19M | · | · | $42M | $37M | · | · | · | · | · | · | · | · | · | · | |
| Operating Income | $11M | $15M | $14M | $-5M | $-17M | $-13M | $-26M | $-32M | $-30M | $-33M | $-4M | $-46M | $-55M | $-54M | $-58M | $-42M | |
| Interest Income | $121.0K | $21.0K | $29.0K | $74.0K | $54.0K | $188.0K | $429.0K | $1M | $539.0K | $808.0K | · | · | · | · | · | · | |
| Other Non-op | $3M | $39M | $-9M | $82M | $-12.0K | $-264.0K | $-224.0K | $19.0K | $7M | $-1M | $-201.0K | $442.0K | $-244.0K | $40.0K | $980.0K | $537.0K | |
| Net Income | $-567.0K | $39M | $-11M | $64M | $-30M | $-26M | $-47M | $-67M | $-55M | $-63M | $-49M | $-65M | $-73M | $-71M | $-74M | $-57M | |
| EPS (Basic) | $-0.01 | $1.03 | $0.03 | $2.00 | $-1.00 | $-1.03 | $-1.95 | $-3.08 | $-2.52 | $-3.04 | $-2.22 | $-3.29 | $-3.93 | $-4.31 | $-15.09 | $-0.19 | |
| EPS (Diluted) | $-0.01 | $1.02 | $0.09 | $1.94 | $-1.00 | $-1.03 | $-1.95 | $-3.08 | $-2.52 | $-3.04 | $-2.22 | $-3.29 | $-3.93 | $-4.31 | $-15.09 | $-0.19 | |
| Shares (Basic) | 41,338,000 | 37,941,000 | · | 31,886,000 | 28,117,000 | 24,469,000 | · | 21,550,000 | 21,062,000 | 20,368,000 | · | 18,908,000 | 17,569,000 | 15,855,000 | · | 286,854 | |
| Shares (Diluted) | 41,338,000 | 38,285,000 | · | 32,858,000 | 28,117,000 | 24,469,000 | · | 21,550,000 | 21,062,000 | 20,368,000 | · | 18,908,000 | 17,569,000 | 15,855,000 | · | 286,854 | |
| EBITDA | $11M | $15M | · | $-5M | $-17M | $-13M | · | $-32M | $-30M | $-33M | · | $-46M | $-55M | $-54M | · | $-42M |
الميزانية العمومية
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19M | $35M | $3M | $3M | $10M | $18M | $40M | $45M | $94M | $53M | $76M | $106M | $143M | $165M | $179M | $208M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | · | · | · | $15M | $24M | · | $10M | |
| Receivables | $15M | $7M | $2M | $538.0K | $709.0K | $354.0K | $407.0K | $207.0K | $719.0K | $476.0K | · | $1M | $1M | $1M | · | $9M | |
| Prepaid Expense | $3M | $4M | $785.0K | $885.0K | $1M | $2M | $2M | $2M | $2M | $4M | · | $16M | $9M | $11M | · | $22M | |
| Other Current Assets | $2M | $2M | $1M | $1M | $2M | $2M | $2M | $3M | $3M | $3M | · | $2M | $3M | $4M | · | $2M | |
| Current Assets | $79M | $95M | $133M | $134M | $13M | $23M | $46M | $50M | $100M | $60M | · | $126M | $171M | $206M | · | $251M | |
| PP&E (Net) | $14M | $15M | $15M | $16M | $113M | $117M | $120M | $124M | $128M | $130M | · | $140M | $143M | $140M | · | $101M | |
| PP&E (Gross) | · | · | $63M | · | · | · | $193M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $48M | $48M | $47M | $47M | $75M | $76M | $73M | $71M | $68M | $65M | · | $61M | $58M | $56M | · | $53M | |
| Goodwill | $24M | $24M | $24M | $24M | $24M | $24M | $24M | $25M | $25M | $25M | · | $25M | $25M | $26M | · | $24M | |
| Intangibles | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $4M | $4M | $4M | · | $4M | $5M | $6M | · | $7M | |
| Other Non-current Assets | $4M | $3M | $3M | $3M | $5M | $6M | $6M | $7M | $7M | $8M | · | $11M | $9M | $4M | · | $8M | |
| Total Assets | $173M | $186M | $227M | $234M | $185M | $200M | $226M | $238M | $292M | $257M | · | $335M | $384M | $413M | · | $429M | |
| Accounts Payable | $59M | $71M | $83M | $85M | $74M | $64M | $61M | $46M | $51M | $51M | · | $41M | $52M | $47M | · | $40M | |
| Accrued Liabilities | $28M | $37M | $34M | $32M | $39M | $36M | $35M | $37M | $41M | $41M | · | $38M | $30M | $33M | · | $29M | |
| Current Liabilities | $232M | $249M | $323M | $287M | $235M | $208M | $221M | $271M | $271M | $256M | · | $198M | $204M | $191M | · | $173M | |
| Capital Leases | $10M | $10M | $10M | $10M | $53M | $54M | $55M | $55M | $56M | $62M | · | $63M | $62M | $63M | · | $64M | |
| Other Non-current Liabilities | $247.0K | $247.0K | $259.0K | $376.0K | $752.0K | $761.0K | $738.0K | $777.0K | $1M | $3M | · | $8M | $11M | $14M | · | $1M | |
| Long-term Debt | $30M | $30M | $45M | $34M | $34M | $34M | $33M | $13M | $13M | $14M | · | $13M | $13M | $14M | · | · | |
| Total Debt | $30M | $30M | · | $34M | $34M | $34M | · | $13M | $13M | $14M | · | $13M | $13M | $14M | · | $13M | |
| Common Stock | $427.0K | $385.0K | $353.0K | $329.0K | $300.0K | $266.0K | $236.0K | $217.0K | $211.0K | $210.0K | · | $4M | $4M | $3M | · | $3M | |
| Paid-in Capital | $1.95B | $1.92B | $1.91B | $1.90B | $1.88B | $1.87B | $1.86B | $1.85B | $1.83B | $1.82B | · | $1.78B | $1.75B | $1.72B | · | $1.61B | |
| Retained Earnings | $-2.14B | $-2.14B | $-2.18B | $-2.17B | $-2.24B | $-2.21B | $-2.18B | $-2.14B | $-2.07B | $-2.02B | · | $-1.91B | $-1.85B | $-1.78B | · | $-1.64B | |
| AOCI | $-450.0K | $-437.0K | $-439.0K | $-2M | $-2M | $-1M | $-1M | $-1M | $-1M | $-1M | · | $-1M | $-717.0K | $917.0K | · | $644.0K | |
| Stockholders' Equity | $-199M | $-221M | $-271M | $-274M | $-355M | $-342M | $-326M | $-292M | $-241M | $-201M | · | $-129M | $-93M | $-59M | · | $-20M | |
| Liabilities + Equity | $173M | $186M | $227M | $234M | $185M | $200M | $226M | $238M | $292M | $257M | · | $335M | $384M | $413M | · | $429M | |
| Shares Outstanding | 42,615,618 | 38,521,761 | 35,320,397 | 32,814,429 | 30,004,430 | 26,563,545 | 23,634,670 | 21,685,192 | 21,126,226 | 20,994,143 | · | · | · | · | · | · |
التدفق النقدي
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $517.0K | $583.0K | $597.0K | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $5M | $3M | $3M | $3M | $2M | $2M | |
| Stock-based Comp | $4M | $1M | $3M | $3M | $4M | $3M | $5M | $5M | $4M | $4M | $5M | $6M | $6M | $5M | $4M | $4M | |
| Operating Cash Flow | $-31M | $-36M | $-17M | $-15M | $-20M | $-26M | $-29M | $-53M | $-38M | $-38M | $-40M | $-65M | $-60M | $-59M | $-47M | $-32M | |
| CapEx | $0 | $0 | $0 | $0 | $1.0K | $5.0K | $73.0K | $7.0K | $461.0K | $35.0K | $223.0K | $3M | $4M | $2M | $14M | $16M | |
| Investing Cash Flow | $267.0K | $69M | $780.0K | $76.0K | $281.0K | $57.0K | $-21.0K | $56.0K | $-237.0K | $229.0K | $3M | $12M | $517.0K | $-11M | $-6M | $-16M | |
| Net Debt Issued | · | $-8M | · | · | · | $-2M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $15M | $-993.0K | $15M | $7M | $11M | $4M | $24M | $5M | $79M | $15M | $7M | $18M | $38M | $56M | $24M | $28M | |
| Net Change in Cash | $-16M | $32M | $-460.0K | $-8M | $-9M | $-22M | $-4M | $-49M | $41M | $-23M | $-30M | $-36M | $-22M | $-14M | $-30M | $-20M | |
| Free Cash Flow | · | $-36M | · | · | · | $-26M | · | · | · | $-38M | · | · | · | $-60M | · | · |
الربحية
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 32.7% | 44.6% | · | -15.0% | -65.0% | -55.3% | · | -125.4% | -128.4% | -117.4% | · | -190.6% | -216.1% | -237.3% | · | -182.9% | |
| Net Margin | -1.6% | 116.2% | · | 211.4% | -116.8% | -109.6% | · | -267.7% | -233.1% | -226.6% | · | -265.4% | -290.3% | -309.6% | · | -249.1% | |
| EBITDA Margin | 32.7% | 44.6% | · | -15.0% | -65.0% | -55.3% | · | -125.4% | -128.4% | -117.4% | · | -190.6% | -216.1% | -237.3% | · | -182.9% | |
| ROA | -0.32% | 20.3% | · | 27.1% | -12.6% | -11.6% | · | -23.4% | -16.2% | -19.0% | · | -16.9% | -17.5% | -16.6% | · | -13.1% | |
| ROE | 0.20% | -13.9% | · | -22.6% | 10.1% | 9.7% | · | 31.9% | 32.8% | 48.8% | · | 86.3% | 163.6% | 331.1% | · | -528.3% |
السيولة والملاءة
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.3 | 0.4 | · | 0.5 | 0.1 | 0.1 | · | 0.2 | 0.4 | 0.2 | · | 0.6 | 0.8 | 1.1 | · | 1.5 | |
| Quick Ratio | 0.1 | 0.2 | · | 0.0 | 0.0 | 0.1 | · | 0.2 | 0.3 | 0.2 | · | 0.5 | 0.8 | 1.0 | · | 1.3 | |
| Debt / Equity | -0.2 | -0.1 | · | -0.1 | -0.1 | -0.1 | · | -0.0 | -0.1 | -0.1 | · | -0.1 | -0.1 | -0.2 | · | -0.7 | |
| LT Debt / Equity | · | · | · | -0.1 | -0.1 | -0.1 | · | 0.0 | 0.0 | 0.0 | · | -0.1 | -0.1 | -0.2 | · | · |
الكفاءة
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 4.5 | 9.8 | · | 81.2 | 36.0 | 58.0 | · | 40.6 | 22.8 | 29.6 | · | 4.9 | 2.5 | 16.9 | · | 1.5 |
لكل سهم
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-4.67 | $-5.74 | · | $-8.35 | $-11.82 | $-12.87 | · | $-13.48 | $-11.42 | $-9.59 | · | · | · | · | · | · | |
| Revenue / Share | $0.83 | $0.88 | · | $0.92 | $0.91 | $0.98 | · | $1.17 | $1.12 | $1.38 | · | $64.30 | $71.99 | $72.22 | · | $79.39 | |
| Cash Flow / Share | · | $-0.94 | · | · | · | $-1.05 | · | · | · | $-1.88 | · | · | · | $-184.56 | · | · | |
| Cash / Share | $0.44 | $0.91 | · | $0.11 | $0.32 | $0.70 | · | $2.07 | $4.44 | $2.52 | · | · | · | · | · | · | |
| EPS (TTM) | $3.04 | $2.05 | · | $-2.04 | $-7.06 | $-8.58 | · | $-10.86 | $-11.07 | $-12.48 | · | $-26.62 | $-23.52 | $-19.76 | · | $-0.84 |
التقييم (آخر 12 شهرًا)
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $133M | $124M | · | $107M | $102M | $100M | · | $160M | $160M | $161M | · | $101M | $99M | $95M | · | $90M | |
| Net Income TTM | $92M | $62M | · | $-39M | $-170M | $-195M | · | $-234M | $-231M | $-250M | · | $-283M | $-275M | $-251M | · | $-224M | |
| Market Cap | $130M | $129M | · | $126M | $137M | $40M | · | $119M | $354M | $244M | · | · | · | · | · | · | |
| Enterprise Value | $142M | $124M | · | $157M | $161M | $55M | · | $87M | $274M | $204M | · | · | · | · | · | · | |
| P/E | 1.0 | 1.6 | · | -1.9 | -0.6 | -0.2 | · | -0.5 | -1.5 | -0.9 | · | -0.8 | -1.4 | -1.5 | · | -47.9 | |
| P/S | 1.0 | 1.0 | · | 1.2 | 1.3 | 0.4 | · | 0.7 | 2.2 | 1.5 | · | · | · | · | · | · | |
| P/B | -0.7 | -0.6 | · | -0.5 | -0.4 | -0.1 | · | -0.4 | -1.5 | -1.2 | · | · | · | · | · | · | |
| P / Cash Flow | · | -3.6 | · | · | · | -1.6 | · | · | · | -6.4 | · | · | · | · | · | · | |
| EV / Revenue | 1.1 | 1.0 | · | 1.5 | 1.6 | 0.6 | · | 0.5 | 1.7 | 1.3 | · | · | · | · | · | · | |
| Earnings Yield | 99.4% | 61.4% | · | -53.0% | -154.5% | -568.2% | · | -198.2% | -66.1% | -107.6% | · | -117.8% | -73.5% | -66.2% | · | -2.1% |
أحدث فترة على اليسار · القيم الفارغة معروضة كـ ·
القوائم المالية قائمة الدخل، الميزانية العمومية، التدفقات النقدية — سنويًا، آخر 5 سنوات
| المقياس | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| الإيرادات | $114M | $103M | $156M | $98M | $296M |
| هامش الربح التشغيلي % | -17.7% | -116.4% | -102.1% | -183.0% | 8.7% |
| صافي الدخل | $-3M | $-232M | $-257M | $-231M | $-29M |
| EPS المخفف | $0.00 | $-10.59 | $-13.75 | $-15.64 | $-0.11 |
| المقياس | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| الدين / حقوق الملكية | -0.2 | -0.1 | -0.1 | -0.2 | 0.4 |
| النسبة الحالية | 0.4 | 0.2 | 0.4 | 1.1 | 2.1 |
| النسبة السريعة | 0.0 | 0.2 | 0.4 | 1.0 | 2.0 |
| المقياس | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| التدفق النقدي الحر | $-77M | $-159M | $-234M | $-228M | $-24M |
الملاك المؤسسيون (13F) 116 مقدمي إقرار · $53.2M إجمالي · حتى تاريخ 30 يونيو، 2026
المؤسسات التي تبلغ عن حيازتها لهذا السهم في نموذج SEC 13F ربع السنوي الخاص بها. المراكز الطويلة فقط؛ قد يظهر مقدم واحد مرتين لأرجل خيارات منفصلة. الأرجل الكبيرة المتعاكسة من خيارات البيع/الشراء تعكس عادةً صناعة السوق أو المخزون المتحوط، وليس القناعة الاتجاهية.
| مراكز جديدة | المراكز الخارجة | زيادة | انخفض | صافي التغير في الأسهم |
|---|---|---|---|---|
| 32 (+18 مقابل الربع السابق) | 14 (-3 مقابل الربع السابق) | 33 (+15 مقابل الربع السابق) | 21 (-12 مقابل الربع السابق) | +5.0M |
مقارنة بـ Q1 2026. المواعيد النهائية لتقديم إقرارات نموذج 13F لهيئة الأوراق المالية والبورصات (SEC) هي في غضون 45 يومًا من نهاية الربع بالإضافة إلى فترة سماح قصيرة للمقدمين المتأخرين — يتم تخطي الأرباع التي لا تزال ضمن هذه النافذة لصالح أحدث زوج تم الإبلاغ عنه بالكامل.
| مؤسسة | القيمة | الأسهم | % من 13F المتتبعة | النوع |
|---|---|---|---|---|
| VANGUARD GROUP INC | $8888511 | 2830736 | 16,72% | الأسهم |
| BlackRock, Inc. | $7848543 | 2564884 | 14,76% | الأسهم |
| VANGUARD CAPITAL MANAGEMENT LLC | $5128854 | 1676096 | 9,65% | الأسهم |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $4368416 | 1427587 | 8,22% | الأسهم |
| Siren, L.L.C. | $3256605 | 1064250 | 6,12% | الأسهم |
| GEODE CAPITAL MANAGEMENT, LLC | $3168086 | 1035040 | 5,96% | الأسهم |
| MACKENZIE FINANCIAL CORP | $2185376 | 714175 | 4,11% | الأسهم |
| GOLDMAN SACHS GROUP INC | $1372052 | 448383 | 2,58% | الأسهم |
| MARSHALL WACE, LLP | $1345239 | 439621 | 2,53% | الأسهم |
| RAYMOND JAMES FINANCIAL INC | $1316038 | 430078 | 2,48% | الأسهم |
| GLOBEFLEX CAPITAL L P | $1280858 | 418581 | 2,41% | الأسهم |
| STATE STREET CORP | $1261892 | 412383 | 2,37% | الأسهم |
| Man Group plc | $1041701 | 340425 | 1,96% | الأسهم |
| NORTHERN TRUST CORP | $961000 | 314052 | 1,81% | الأسهم |
| Connor, Clark & Lunn Investment Management Ltd. | $948707 | 310035 | 1,78% | الأسهم |
| VANGUARD FIDUCIARY TRUST CO | $831139 | 271614 | 1,56% | الأسهم |
| MORGAN STANLEY | $801929 | 262068 | 1,51% | الأسهم |
| RENAISSANCE TECHNOLOGIES LLC | $698739 | 228346 | 1,31% | الأسهم |
| PANAGORA ASSET MANAGEMENT INC | $549542 | 179589 | 1,03% | الأسهم |
| Susquehanna Portfolio Strategies, LLC | $485735 | 158737 | 0,91% | الأسهم |
| Cubist Systematic Strategies, LLC | $393512 | 102211 | 0,74% | الأسهم |
| Jump Financial, LLC | $318182 | 103981 | 0,60% | الأسهم |
| Bank of New York Mellon Corp | $311424 | 101773 | 0,59% | الأسهم |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $304140 | 99392 | 0,57% | الأسهم |
| TWO SIGMA INVESTMENTS, LP | $301976 | 98685 | 0,57% | الأسهم |
| STRS OHIO | $235314 | 76900 | 0,44% | الأسهم |
| CANADA PENSION PLAN INVESTMENT BOARD | $205326 | 67100 | 0,39% | الأسهم |
| BANK OF AMERICA CORP /DE/ | $159157 | 52012 | 0,30% | الأسهم |
| Invesco Ltd. | $155870 | 50938 | 0,29% | الأسهم |
| WELLS FARGO & COMPANY/MN | $132245 | 43217 | 0,25% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $128569 | 42016 | 0,24% | الأسهم |
| Avestar Capital, LLC | $125460 | 41000 | 0,24% | الأسهم |
| DEUTSCHE BANK AG\ | $119046 | 38904 | 0,22% | الأسهم |
| TWO SIGMA ADVISERS, LP | $107529 | 34245 | 0,20% | الأسهم |
| Claro Advisors Inc. | $102051 | 33350 | 0,19% | الأسهم |
| XTX Topco Ltd | $96849 | 31650 | 0,18% | الأسهم |
| CITADEL ADVISORS LLC | $90270 | 29500 | 0,17% | عقد خيار الشراء |
| RHUMBLINE ADVISERS | $90226 | 29488 | 0,17% | الأسهم |
| CAPTRUST FINANCIAL ADVISORS | $88654 | 28972 | 0,17% | الأسهم |
| Engineers Gate Manager LP | $85092 | 27808 | 0,16% | الأسهم |
| CITIGROUP INC | $84768 | 27702 | 0,16% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $77418 | 25300 | 0,15% | عقد خيار الشراء |
| LPL Financial LLC | $73948 | 24166 | 0,14% | الأسهم |
| Key Client Fiduciary Advisors, LLC | $73823 | 24125 | 0,14% | الأسهم |
| OSAIC HOLDINGS, INC. | $71786 | 23460 | 0,14% | الأسهم |
| BNP PARIBAS FINANCIAL MARKETS | $67002 | 21896 | 0,13% | الأسهم |
| WOLVERINE TRADING, LLC | $63282 | 15900 | 0,12% | عقد خيار الشراء |
| CITADEL ADVISORS LLC | $62730 | 20500 | 0,12% | عقد خيار البيع |
| PRELUDE CAPITAL MANAGEMENT, LLC | $60469 | 19761 | 0,11% | الأسهم |
| PRUDENTIAL FINANCIAL INC | $59395 | 19410 | 0,11% | الأسهم |
الناشطون والمالكون بنسبة 5%+ 5 حيازات
المستثمرون الذين قدموا الجدول الزمني 13D لدى هيئة الأوراق المالية والبورصات — ملكية مستفيدة تزيد عن 5% مع نية التأثير على المُصدر (حصص الناشطين، حملات مجلس الإدارة، الاندماج والاستحواذ). يعرض كل صف أحدث حالة معروفة لمركز مقدم الطلب هذا.
| مقدم | مقدم | حصة | الحالة | الغرض | إيداع |
|---|---|---|---|---|---|
| ZYNEXT VENTURES USA LLC, ZYNEXT VENTURES PTE LTD, ZYDUS LIFESCIENCES LTD | 23 يناير، 2026 | 5,90% | إيداع أولي | · | SEC |
| Agenus Inc. (“Agenus”) ×3 إيداعات | 26 مايو، 2023 | · | إيداع أولي | استثمار سلبي | SEC |
| Garo H. Armen | 22 يناير، 2008 | · | إيداع أولي | استثمار سلبي | SEC |
| Brad M. Kelley 2) ×4 إيداعات | 27 فبراير، 2003 | · | إيداع أولي | · | SEC |
| شخص مُبلِّغ لم يُكشف عنه | 1 مايو، 2001 | · | إيداع أولي | اندماج واستحواذ / بيع | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
المطلعون على الشركة 46 من المطلعين · مسؤولون 7 · مديرون 7
| مطلع | الدور | آخر نشاط | الأسهم المملوكة | مشتريات 12 شهرًا | مبيعات 12 شهرًا | صافي 12 شهرًا |
|---|---|---|---|---|---|---|
| Jeff D Clark | Chief Financial Officer | 18 فبراير، 2004 A | · | 0 | 0 | $0 |
| Austin Charette | Principal Accounting Officer | 24 إبريل، 2026 A | · | 0 | 0 | $0 |
| Christine M Klaskin | PFO & PAO | 18 يونيو، 2025 A | 23478 | 0 | 0 | $0 |
| Evan Kearns | VP and General Counsel | 17 ديسمبر، 2020 A | · | 0 | 0 | $0 |
| Christian Cortis | Chief Strategy Officer | 23 يوليو، 2019 A | · | 0 | 0 | $0 |
| Alex Duncan | Chief Technology Officer | 23 يوليو، 2019 A | 21026 | 0 | 0 | $0 |
| Neal Gordon | SrVP, Manufacturing Operations | 18 فبراير، 2004 A | · | 0 | 0 | $0 |
| Timothy Wright | مدير | 1 أكتوبر، 2026 A | 50391 | 0 | 0 | $0 |
| Thomas L Harrison | مدير | 1 أكتوبر، 2026 A | 51988 | 0 | 0 | $0 |
| Marco Tullio Marcucci | مدير | 5 أغسطس، 2026 A | · | 0 | 0 | $0 |
| Ulf Wiinberg | مدير | 1 أكتوبر، 2024 A | 124063 | 0 | 0 | $0 |
| Allison M Jeynes-Ellis | مدير | 5 فبراير، 2024 A | 66176 | 0 | 0 | $0 |
| Wadih Jordan | مدير | 3 أكتوبر، 2022 A | · | 0 | 0 | $0 |
| Paul N Clark | مدير | 1 إبريل، 2021 A | · | 0 | 0 | $0 |
| INCYTE CORP | مالك 10% | 17 يونيو، 2020 S | 16972968 | 0 | 0 | $0 |
| Brad M Kelley | مالك 10% | 24 سبتمبر، 2003 P | 5546740 | 0 | 0 | $0 |
| Garo H Armen | · | 10 أغسطس، 2026 A | 371108 | 0 | 0 | $0 |
| Steven J O'Day | · | 5 أغسطس، 2026 A | 57116 | 0 | 0 | $0 |
| Susan B Hirsch | · | 5 أغسطس، 2026 A | 108725 | 0 | 0 | $0 |
| Jennifer Buell | · | 5 أغسطس، 2026 A | 19738 | 0 | 0 | $0 |
| Brian Corvese | · | 5 أغسطس، 2026 A | 92085 | 0 | 0 | $0 |
| Adam Krauss | · | 15 يونيو، 2021 A | · | 0 | 0 | $0 |
| Shalini Sharp | · | 21 يونيو، 2018 A | 104270 | 0 | 0 | $0 |
| Ozer Baysal | · | 20 يونيو، 2018 A | 58790 | 0 | 0 | $0 |
| Karen Valentine | · | 20 يونيو، 2018 A | 101521 | 0 | 0 | $0 |
| Jean-Marie Cuillerot | · | 31 مارس، 2017 A | · | 0 | 0 | $0 |
| Robert Benjamin Stein | · | 31 مارس، 2017 A | 20986 | 0 | 0 | $0 |
| Shahzad Malik | · | 15 يونيو، 2016 A | 1587302 | 0 | 0 | $0 |
| Charles Evan Ballantyne | · | 14 يونيو، 2016 A | 24795 | 0 | 0 | $0 |
| Tom Dechaene | · | 4 يناير، 2016 A | · | 0 | 0 | $0 |
| Kerry Wentworth | · | 26 فبراير، 2014 S | 57410 | 0 | 0 | $0 |
| John Hatsopoulos | · | 3 أكتوبر، 2011 A | 65000 | 0 | 0 | $0 |
| ROTHWELL TIMOTHY G | · | 3 أكتوبر، 2011 J | 7389 | 0 | 0 | $0 |
| Hyam Levitsky | · | 1 يوليو، 2011 A | 15376 | 0 | 0 | $0 |
| Peter Thornton | · | 5 يونيو، 2008 A | 5000 | 0 | 0 | $0 |
| Eisen Margaret | · | 5 يونيو، 2008 A | 20000 | 0 | 0 | $0 |
| AFEYAN NOUBAR | · | 2 إبريل، 2007 A | 0 | 0 | 0 | $0 |
| ATLEE FRANK V III | · | 2 إبريل، 2007 A | 0 | 0 | 0 | $0 |
| Pramod Srivastava | · | 9 فبراير، 2007 S | 1610 | 0 | 0 | $0 |
| Roman Chicz | · | 5 يناير، 2007 A | · | 0 | 0 | $0 |
| Mark Kessel | · | 2 أكتوبر، 2006 A | · | 0 | 0 | $0 |
| Bruce Leicher | · | 15 سبتمبر، 2006 A | · | 0 | 0 | $0 |
| Alastair Jj Wood | · | 15 يونيو، 2006 A | · | 0 | 0 | $0 |
| Gamil De Chadarevian | · | 28 فبراير، 2006 M | 88610 | 0 | 0 | $0 |
| Renu Gupta | · | 24 فبراير، 2006 A | · | 0 | 0 | $0 |
| Russell Herndon | · | 8 ديسمبر، 2004 A | · | 0 | 0 | $0 |
المطلعون من إيداعات SEC Form 3/4/5؛ صافي = سوق مفتوح فقط
ملكية صناديق المؤشرات المتداولة محتفظ بها بواسطة 12 صناديق مؤشرات متداولة
الوزن يعكس فقط ممتلكات الأسهم المباشرة (N-PORT)؛ قد تحتفظ الصناديق المضاعفة أو القائمة على المشتقات بتعرض إضافي للمقايضة غير معروض.
| صندوق | الوزن | الوحدات | حتى تاريخ | المصدر |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,68% | 15754 SH | 1 أكتوبر، 2026 | يومي |
| IWC · iShares Trust | 0,06% | 134978 SH | 11 سبتمبر، 2026 | يومي |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,01% | 29536 SH | 19 أغسطس، 2026 | يومي |
| RSSL · Global X Funds | 0,01% | 19052 NS | 31 يوليو، 2026 | N-PORT |
| IWM · iShares Trust | 0,01% | 1003811 SH | 11 سبتمبر، 2026 | يومي |
| IWO · iShares Trust | 0,01% | 137756 SH | 11 سبتمبر، 2026 | يومي |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 485158 SH | 19 أغسطس، 2026 | يومي |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1159672 SH | 19 أغسطس، 2026 | يومي |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,00% | 230345 SH | 19 أغسطس، 2026 | يومي |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,00% | 6460 SH | 19 أغسطس، 2026 | يومي |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 5125 SH | 19 أغسطس، 2026 | يومي |
| IWN · iShares Trust | · | 310686 SH | 11 سبتمبر، 2026 | يومي |
AGEN توافق الآراء التحليلي آراء المحللين الصعودية والهبوطية، السعر المستهدف لمدة 12 شهرًا، الصعود
السعر المستهدف لمدة 12 شهرًا
3 محللين · 2026-09-27السعر المستهدف المتوسط $26.33 +215,0%
مقارنة الأقران (الصناعة الفرعية GICS) المقاييس الرئيسية مقابل أقران القطاع
أساس السنة المالية، الأسعار كما في إغلاق نهاية السنة المالية الأخيرة لكل شركة.
| الرمز | القيمة السوقية | P/E | الإيرادات سنويًا | هامش الربح الصافي | ROE | هامش الربح الإجمالي |
|---|---|---|---|---|---|---|
| AGEN | $111M | · | 10.4% | -2.7% | 1.0% | · |
| EDIT | $201M | -1.1 | 25.4% | -395.0% | -688.8% | · |
| GALT | $271M | -8.7 | · | · | 25.0% | · |
| IRD | $140M | -2.5 | 29.1% | -349.3% | -302.2% | · |
| XFOR | $364M | -2.1 | 150.0% | -1218.5% | -83.2% | · |
| RCEL | $105M | -2.0 | 11.5% | -67.8% | 328.9% | 82.1% |
| ENTA | $256M | -3.1 | -3.4% | -125.4% | -103.5% | · |
| ARCT | $174M | -2.6 | -46.1% | -80.2% | -29.6% | · |
مقاييسي قائمة المراقبة الشخصية الخاصة بك — صفوف مختارة من الأساسيات الكاملة
اختر المقاييس التي تهمك — انقر فوق علامة + بجوار أي صف في الأساسيات الكاملة أعلاه.
يتم حفظ اختيارك ويتبعك عبر جميع الأسهم.